Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Mitomycin C (MMC) and Interferon α2B (IFNα2B) in the management of ocular surface squamous neoplasia (OSSN): when does it help?

Search Title by author or title

Session Details

Session Title: Cornea: Medical

Session Date/Time: Tuesday 10/10/2017 | 08:00-10:30

Paper Time: 08:54

Venue: Room 3.6

First Author: : R.Rajagopal INDIA

Co Author(s): :    K. Popat   G. Iyer   B. Srinivasan              

Abstract Details

Purpose:

Topical MMC and IFNα2B have rarely been used as a primary modality of treatment in OSSN either for chemo reduction before surgery (lesions > 6 clock hrs / multifocal) or chemotherapy (localised/corneal lesions). We reviewed indications and outcome of the same.

Setting:

Department of Cornea and Refractive Surgery, Medical Research Foundation, Chennai, India

Methods:

Case records of 13 patients primarily treated with either 0.04% MMC (9), IFNα2B (1 million IU/ml) (2) or both sequentially (2) were reviewed : Commonest morphology was papillomatous (7).

Results:

Papillomatous lesions responded the best (57.14%).Chemoreduction was initiated in 5 eyes (4 MMC/1 IFNα2B-epithelial toxicity)- lesions completely resolved in 3 (papillomatous) (1 MMC,1 IFNα2B, 1 MMC followed by IFNα2B).1 had partial response followed by surgery (corneal),1 lost to follow up(LTFU). Chemotherapy was initiated in 8 (7 MMC, 1 IFNα2B - patient opted). Complete resolution occurred in 2 (IFNα2B 1, MMC followed by IFNα2B 1) with no recurrence over 24 months. Mean time to resolution was 3 months. 3 eyes showed partial response and underwent surgical excision- 2 had no response (operated),1was LTFU.No toxicity was observed.

Conclusions:

Primary chemotherapy should be considered in papillomatous, multifocal and/or diffuse lesions. Toxicity is seldom seen. MMC is preferred in papillomatous lesions and is cost effective, while Interferon is preferred in pre-existing epithelial changes.

Financial Disclosure:

NONE

Back to previous